Beyond market averages, investors seeking exceptional growth focus on the art of stock selection. The right picks can significantly contribute to the expansion of your wealth.
In the latest session, Amylyx Pharmaceuticals Inc (NASDAQ: AMLX) closed at $3.18 down -9.14% from its previous closing price of $3.50. In other words, the price has decreased by -$9.14 from its previous closing price. On the day, 1.36 million shares were traded. AMLX stock price reached its highest trading level at $3.48 during the session, while it also had its lowest trading level at $3.095.
Ratios:
For a deeper understanding of Amylyx Pharmaceuticals Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 4.55 and its Current Ratio is at 4.55. In the meantime, Its Debt-to-Equity ratio is 0.01 whereas as Long-Term Debt/Eq ratio is at 0.00.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, Robert W. Baird on November 18, 2024, Upgraded its rating to Outperform and sets its target price to $11 from $3 previously.
On October 23, 2024, BofA Securities Upgraded its rating to Buy which previously was Neutral and also upped its target price recommendation from $4.20 to $10.
Mizuho Downgraded its Buy to Neutral on March 18, 2024, whereas the target price for the stock was revised from $32 to $4.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Jan 06 ’25 when Klee Justin B. sold 7,471 shares for $4.04 per share. The transaction valued at 30,202 led to the insider holds 3,176,788 shares of the business.
Cohen Joshua B sold 7,471 shares of AMLX for $30,232 on Jan 06 ’25. The Co-Chief Executive Officer now owns 3,213,098 shares after completing the transaction at $4.05 per share. On Dec 02 ’24, another insider, Bedrosian Camille L, who serves as the Chief Medical Officer of the company, sold 5,421 shares for $5.54 each. As a result, the insider received 30,007 and left with 138,380 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, AMLX now has a Market Capitalization of 239917648 and an Enterprise Value of -13845805. For the stock, the TTM Price-to-Sale (P/S) ratio is 1.11 while its Price-to-Book (P/B) ratio in mrq is 1.11. Its current Enterprise Value per Revenue stands at -0.07 whereas that against EBITDA is 0.056.
Stock Price History:
The Beta on a monthly basis for AMLX is -0.51, which has changed by -0.7744845 over the last 52 weeks, in comparison to a change of 0.22263205 over the same period for the S&P500. Over the past 52 weeks, AMLX has reached a high of $19.95, while it has fallen to a 52-week low of $1.58. The 50-Day Moving Average of the stock is -34.70%, while the 200-Day Moving Average is calculated to be 6.16%.
Shares Statistics:
For the past three months, AMLX has traded an average of 1.25M shares per day and 637400 over the past ten days. A total of 68.55M shares are outstanding, with a floating share count of 43.43M. Insiders hold about 36.64% of the company’s shares, while institutions hold 60.23% stake in the company. Shares short for AMLX as of 1734048000 were 1565509 with a Short Ratio of 1.56, compared to 1731628800 on 1526219. Therefore, it implies a Short% of Shares Outstanding of 1565509 and a Short% of Float of 2.5100000000000002.
